Data were analyzed from June 2024 to March 2025.<h4>Exposure</h4>Preoperative and postoperative levels of CEA, CA19-9, and CA125.<h4>Main outcomes and measures</h4>Association of preoperative and postoperative serum TM levels with tumor burden and likelihood of complete CRS, disease-free survival (DFS), and overall survival (OS).<h4>Results</h4>A total of 421 CRSs were included in the study, 376 (89.3%) of which were performed in patients with AA (229 [60.9%] in females; median age at surgery, 56 [IQR, 47-64] years; 290 [77.1%] were complete CRS). The gene discussed is CEACAM5; the disease is congenital rubella syndrome.